LXEO insider transaction filings
Lexeo Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen LXEO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 14 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings by 4 insiders — 66,326 shares, $299,805 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 25,947 shares @ $4.48 ($116,243) by Townsend Richard Nolan, filed 2026-07-01.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Townsend Richard Nolan — Chief Executive Officer, Director | 2 | — | 2 legs · 29,292 sh · $132,804 | 1 |
| Bhalla Narinder Pal — Chief Medical Officer | 1 | — | 1 leg · 22,306 sh · $98,593 | 1 |
| Tamayo Louis Edward — Chief Financial Officer | 2 | — | 2 legs · 8,758 sh · $41,041 | 1 |
| Otero Jose Manuel — Chief Operating Officer | 2 | — | 2 legs · 5,970 sh · $27,368 | 1 |
| Agger Mette Kirstine — Director | 1 | — | — | 1 |
| Altschuler Steven — Director | 1 | — | — | 1 |
| CHOLMONDELEY PAULA H — Director | 1 | — | — | 1 |
| COOPERSTONE BRENDA — Director | 1 | — | — | 1 |
| DIAZ REINALDO M — Director | 1 | — | — | 1 |
| Tanguler Tolga — Director | 1 | — | — | 1 |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Lexeo Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Otero Jose Manuel — Chief Operating Officer | Sale (S): 1,304 @ $4.96 | EDGAR |
| 2026-08-19 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 3,345 @ $4.95 | EDGAR |
| 2026-08-19 | 4 | Tamayo Louis Edward — Chief Financial Officer | Sale (S): 4,117 @ $4.91 | EDGAR |
| 2026-07-01 | 4 | Bhalla Narinder Pal — Chief Medical Officer | Grant/award (A): 55,000 @ $0 · Sale (S): 22,306 @ $4.42 | EDGAR |
| 2026-07-01 | 4 | Tamayo Louis Edward — Chief Financial Officer | Grant/award (A): 12,000 @ $0 · Sale (S): 4,641 @ $4.49 | EDGAR |
| 2026-07-01 | 4 | Otero Jose Manuel — Chief Operating Officer | Grant/award (A): 12,060 @ $0 · Sale (S): 4,666 @ $4.48 | EDGAR |
| 2026-07-01 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Grant/award (A): 67,000 @ $0 · Sale (S): 25,947 @ $4.48 | EDGAR |
| 2026-06-29 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tanguler Tolga — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Van Hauwermeiren Timothy — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Agger Mette Kirstine — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Altschuler Steven — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | DIAZ REINALDO M — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | CHOLMONDELEY PAULA H — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Otero Jose Manuel — Chief Operating Officer | Sale (S): 1,302 @ $5.07 | EDGAR |
| 2026-05-20 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 3,342 @ $5.06 | EDGAR |
| 2026-04-30 | 4 | Sepp-Lorenzino Laura — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 55,000 @ $5.69 | EDGAR |
| 2026-03-17 | 4 | Otero Jose Manuel — Chief Operating Officer | Grant/award (A): 5,930 @ $2.64 | EDGAR |
| 2026-03-17 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Grant/award (A): 2,623 @ $2.64 | EDGAR |
| 2026-02-20 | 4 | Otero Jose Manuel — Chief Operating Officer | Sale (S): 3,016 @ $6.40 | EDGAR |
| 2026-02-20 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 10,173 @ $6.38 | EDGAR |
| 2026-02-20 | 4/A | Otero Jose Manuel — Chief Operating Officer | Sale (S): 721 @ $9.27 | EDGAR |
| 2026-02-17 | 4 | Bhalla Narinder Pal — Chief Medical Officer | Grant/award (A): 49,500 @ $0 · Grant/award (A): 297,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Tamayo Louis Edward — Chief Financial Officer | Grant/award (A): 44,665 @ $0 · Grant/award (A): 226,665 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Otero Jose Manuel — Chief Operating Officer | Grant/award (A): 65,000 @ $0 · Grant/award (A): 260,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Grant/award (A): 161,665 @ $0 · Grant/award (A): 646,665 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | Otero Jose Manuel — Chief Technical Officer | Sale (S): 721 @ $9.27 | EDGAR |
| 2025-11-20 | 4 | See Tai Sandi — Chief Development Officer | Sale (S): 386 @ $9.27 | EDGAR |
| 2025-11-20 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 1,127 @ $9.27 | EDGAR |
| 2025-11-20 | 4 | Robertson Jenny — Chief Legal Officer | Sale (S): 549 @ $9.27 | EDGAR |
| 2025-11-20 | 4 | Adler Eric — Chief Medical Officer | Sale (S): 615 @ $9.27 | EDGAR |
| 2025-10-17 | 4 | Otero Jose Manuel — Chief Technical Officer | Grant/award (A): 5,940 @ $0 · Sale (S): 2,091 @ $8.94 · Sale (S): 24 @ $9.56 | EDGAR |
| 2025-10-17 | 4 | See Tai Sandi — Chief Development Officer | Grant/award (A): 10,890 @ $0 · Sale (S): 3,844 @ $8.94 · Sale (S): 44 @ $9.56 | EDGAR |
| 2025-10-17 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Grant/award (A): 33,000 @ $0 · Sale (S): 12,985 @ $8.94 · Sale (S): 148 @ $9.56 | EDGAR |
| 2025-10-17 | 4 | Robertson Jenny — Chief Legal Officer | Grant/award (A): 9,900 @ $0 · Sale (S): 3,486 @ $8.94 · Sale (S): 40 @ $9.56 | EDGAR |
| 2025-10-17 | 4 | Adler Eric — Chief Medical Officer | Grant/award (A): 9,570 @ $0 · Sale (S): 3,344 @ $8.94 · Sale (S): 38 @ $9.56 | EDGAR |
| 2025-09-16 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Grant/award (A): 2,193 @ $2.64 | EDGAR |
| 2025-09-10 | 4/A | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 1,115 @ $4.67 | EDGAR |
| 2025-09-03 | 4 | Tamayo Louis Edward — Chief Financial Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4 | Otero Jose Manuel — Chief Technical Officer | Sale (S): 2,848 @ $4.67 | EDGAR |
| 2025-08-20 | 4 | Robertson Jenny — Chief Legal Officer | Sale (S): 542 @ $4.67 | EDGAR |
| 2025-08-20 | 4 | Adler Eric — Chief Medical Officer | Sale (S): 608 @ $4.67 | EDGAR |
| 2025-08-20 | 4 | Townsend Richard Nolan — Chief Executive Officer, Director | Sale (S): 2,735 @ $4.67 | EDGAR |
| 2025-08-20 | 4 | See Tai Sandi — Chief Development Officer | Sale (S): 382 @ $4.67 | EDGAR |
| 2025-06-30 | 4 | Van Hauwermeiren Timothy — Director | Grant/award (A): 22,916 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Agger Mette Kirstine — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Altschuler Steven — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | DIAZ REINALDO M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | CHOLMONDELEY PAULA H — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Lexeo Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LXEO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →